Pleurotus ostreatus is the second cultivated and most popular edible mushroom after Agaricus bisporus worldwide. As dietary supplements, nutraceuticals like Pleurotus ostreatus that go beyond the usual health benefits of mushrooms are becoming more popular. The objective of this study is to put together a summary of the nutrition information and link it to the possible health benefits and health-improving effects of eating oyster mushrooms. This review is based on secondary data from 102 published articles about P. ostreatus. All papers were examined following predetermined criteria for inclusion and exclusion, and this study contained 83 publications. The high nutritional content and beneficial health effects make P. ostreatus a high-quality food. It makes up for the lack of protein by switching between a diet based on wheat, rice, and maize. Nowadays, P. ostreatus is famous precious functional food ingredients due to the fact they may be cholesterol-free and low in calories, carbohydrates, fat, and sodium. Side by side, they offer crucial nutrients including riboflavin, selenium, potassium, niacin, proteins, and fiber.

Phosphodiesterase-1 (PDE1) is a versatile enzyme that has surprisingly received considerable attention as a possible therapeutic target in Alzheimer’s disease (AD) because it maintains the homeostasis of 3ʹ,5ʹ-cyclic adenosine monophosphate (cAMP) and 3ʹ,5ʹ-cyclic guanosine monophosphate (cGMP) in the brain. 3ʹ,5ʹ-cyclic adenosine monophosphate and 3ʹ,5ʹ-cyclic guanosine monophosphate are the two key second messengers that regulate a broad range of intracellular processes and neurocognitive functions, specifically memory and cognition, associated with Alzheimer’s disease. However, the lack of available selective drugs on the market poses challenges to identifying the beneficial effects of natural products. The present review focuses on Phosphodiesterase-1 and its isoforms, splicing variants, location, distribution, and function; the role of Phosphodiesterase-1 inhibitors in Alzheimer’s disease; and the use of vinpocetine and natural products as specific Phosphodiesterase-1 inhibitors. Moreover, it aims to provide ongoing updates, identify research gaps, and present future perspectives. This review indicates the potential role of Phosphodiesterase-1 inhibitors in the treatment of neurodegenerative disorders, such as Alzheimer’s disease. Certain clinical trials on the alleviation of Alzheimer’s disease in patients are still in progress. Among de novo outcomes, the employment of Phosphodiesterase-1 inhibitors to treat Alzheimer’s disease is an important advancement given the absence of particular therapies in the pipeline for this highly prevalent disease. To sum up, Phosphodiesterase-1 inhibition has been specifically proposed as a critical therapeutic approach for Alzheimer’s disease. This study provides a comprehensive review on the biological and pharmacological aspects of Phosphodiesterase-1, its role on the Alzheimer’s diseases and its significance as Alzheimer’s disease therapeutic target in drug discovery from natural products. This review will help clinical trials and scientific research exploring new entities for the treatment and prevention of Alzheimer’s disease.

Aim: The main purpose of this study was to compare the coronary heart disease between male and female, aged 30 to upto 60 years hailing at Khulna city in Bangladesh, during may, 2014 to November, 2014. Methods and Results: Data were collected by questionnaires on the basis of sex, age, smoking, body mass index and presence or absence of other diseases like kidney and diabetes and then compared between them. 69.1 % Males were found more vulnerable to coronary heart disease than 30.9 % females because their food intake pattern, nutritional status, physical activity and life style. Between 69.1 % male and 30.9 % female; 15.8% male and 1.7% female are in obese, 40.8% male and 13,3% female are overweight, 12.5% male and 9.2 % female are normal where 6.7% female are malnourished and 55.8% male and 24.2% female have hypertension and 60.8% male and 22.5% female are suffer from diabetics and 35.8% male and 22.5% female respondents gain heart disease from family and 54.1% male do smoke all time and 10.0% male respondents intake excess cholesterol and 24.1% male and 19.1% female intake excess cholesterol in sometimes and 30.3% male and 3.3% female have tend on uncooked salt where 27.1% male and 18.4% female have no tend on uncooked salt and 11.7% male and 9.2 % female have tend on uncooked salt for sometimes and 6.7% male are usually drink alcohol and 19.1% male and 9.2% female patients gain LDL cholesterol level above 100 mg/dl and finally 42.5% male and 13.3% female patients gain LDL cholesterol level below 100 mg/dl. Conclusion: This study demonstrates that males are more vulnerable to coronary heart disease than females.